Analyzing Real-World Data & Investigating Genotype-Phenotype Data to Support Precision Medicine Drug Development in Rare Disease…

The recent onset of COVID-19 has advanced the demand for innovation as the pandemic illuminates the fractured and segmented nature of the healthcare system. Due to current social and health restrictions, the crisis hinders traditional clinical trials and drug development. 

At Precision Digital Health (PDH), we are expanding our capabilities to a more patient-centric approach as COVID-19 is impacting high risk populations’ ability to access clinical trial sites.  Accordingly, PDH is expanding its focus on decentralized trials.  This method mitigates the associated health risk exposure and cost burden of travel to the site, while continuing to advance clinical research.  In addition, PDH continues to introduce new devices and mobile features for client use in support of COVID-19 research. 

Precision Digital Health has executed their robust business continuity plan to ensure there are no interruptions for our client services at the same time ensuring data integrity.  We remain committed to ensuring our clients receive the same high level of service.  PDH is continually monitoring the situation to guide us through a strategic plan to adjust to these unprecedented times. We are committed to do our part to protect our families, our employees, our clients and our communities. We are in this together. 

Precision Digital Health, Inc. (PDH) recognizes privacy as both a legal obligation and a critical element of customer service.  PDH leverages real-world data from various patient data sources, such as electronic health records, device data (from both medical devices and wearables) and EDC trial data sourced from our Life Sciences partners. We comply with the United States Federal Drug and Administration (FDA) rules and regulations as well as other regulatory bodies based on the nature of the work. 

PDH has aligned with the Privacy Shield Framework and the BBB EU Privacy Shield as a method to adhere to data protection requirements when transferring personal health information (PHI) data from the European Union and Switzerland to the United States to support transatlantic commerce.  

PDH’s Privacy Shield benefits our partners by helping them navigate our requirements and processes involved with the EU and Swiss Privacy Shield Frameworks which is enforced by the U.S. Federal Trade Commission. 

• PDH Privacy Shield enables the transfer of patient data from European Union and Switzerland to the United States by adhering to relevant compliance with data protection requirements.   

• The Privacy Shield also promotes greater transparency around data collection, use and transfer by demonstrating our privacy practices.  PDH assures protection against loss, misuse, and unauthorized access, disclosure, alteration, and destruction of data that are in place.  This takes into account the risks involved in the processing and nature of the personal health information (PHI) 

• Data integrity is a priority for PDH.  We ensure that data is relevant for the purposes for which it is to be used and that the information is reliable for its intended use while maintaining its accuracy, completeness, and timeliness. 

• PDH is committed to resolving any challenges with individual privacy and collection or use of PHI transferred to the United States pursuant to the Privacy Shield.